Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

GSK plc is a global biopharma company. The Company makes vaccines and specialty medicines to prevent and treat disease. Its segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed a new monoclonal antibody treatment for COVID-19. Its product areas include vaccines, specialty medicines, and general medicines. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions, including the chronic autoimmune condition lupus, respiratory disease, and human immunodeficiency virus (HIV). Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics and medicines for skin diseases. It has a global network of about 12 vaccines manufacturing sites.

  • Revenue in GBP (TTM)31.48bn
  • Net income in GBP3.51bn
  • Incorporated1999
  • Employees90.10k
  • Location
    GSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
  • Phone+44 208 047 5000
  • Fax+44 208 047 7807
  • Websitehttps://www.gsk.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GSK:LSE since
announced
Transaction
value
Affinivax IncDeal completed31 May 202231 May 2022Deal completed-34.47%3.30bn
Sierra Oncology IncDeal completed13 Apr 202213 Apr 2022Deal completed-36.52%2.08bn
Data delayed at least 20 minutes, as of Dec 01 2022 17:03 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
UCB SA5.11bn765.58m12.89bn8.56k16.831.6411.392.524.564.5630.4746.940.40371.824.79691,975.306.057.397.389.3073.0974.3414.9916.730.82836.690.252828.568.046.8544.1314.2129.002.48
argenx SE217.84m-753.87m18.48bn650.00------84.85-16.79-16.794.76--------388,289.60---20.19---22.8683.75---346.06-191.43---7.70----1,105.7398.1632.90--163.70--
Merck KGaA18.80bn3.00bn19.39bn63.72k21.782.674.281.037.987.9850.0865.000.45981.905.18361,073.307.365.009.246.6062.3563.1716.0012.090.858826.730.289.1612.285.5653.7513.4010.889.04
Genmab A/S1.39bn656.15m25.00bn1.56k38.148.00--17.9785.7185.71181.62408.670.4385--2.949,890,264.0020.6818.8722.6820.07----47.1742.62----0.0230.00-16.1136.10-36.7820.4450.07--
HALEON PLC9.87bn1.50bn26.24bn22.80k17.490.9822--2.660.16240.16241.072.89------432,719.30--------62.76--15.68--2.85457.600.2888---3.51--21.40------
Lonza Group AG5.13bn797.01m32.01bn17.15k40.143.6325.376.2412.2141.8778.57134.940.3667----360,648.705.725.007.016.1438.6939.8215.5913.97--13.150.192431.4019.995.53-7.6717.4929.663.33
Bayer AG43.03bn4.06bn46.96bn102.30k11.581.325.981.094.784.7850.7542.010.40281.604.74500,386.403.82-1.375.10-1.7762.3259.999.48-3.730.77244.890.5193--6.484.76106.42-23.200.2547-5.52
GSK plc31.48bn3.51bn57.22bn90.10k14.186.258.311.820.99183.538.632.250.45292.004.14349,349.606.086.969.4211.6165.4168.4813.4314.680.74410.200.717394.850.0444.11-23.7336.904.50-4.36
Sanofi SA38.28bn5.52bn94.61bn95.44k17.00--13.422.475.095.0935.35--------464,659.20--5.19--6.2369.7068.0614.3915.36--46.45--66.944.832.46-49.387.20-0.3872.28
AstraZeneca plc37.45bn1.69bn171.54bn83.10k102.185.8925.114.581.081.0824.0518.810.44841.205.13450,703.202.032.622.683.6679.2578.904.536.610.60956.440.4546196.2640.5810.22-96.50-49.76-1.011.03
Novartis AG43.34bn18.07bn174.80bn108.00k9.043.107.574.039.189.1822.2526.740.43612.226.22473,770.1018.199.0824.0311.5670.9970.6241.7024.731.07--0.318358.805.971.38197.5829.050.63113.44
Novo Nordisk A/S19.40bn6.13bn178.77bn52.70k38.2425.8925.889.2123.1223.1273.1034.140.8021.254.433,498,389.0025.3432.6553.2763.1284.1983.7931.5933.520.73912.980.253050.1810.914.7213.334.72-2.236.47
Roche Holding AG56.45bn12.85bn223.09bn100.92k17.429.7812.753.9517.6717.6777.2031.460.73742.395.73637,960.8018.1915.6227.7023.7769.1871.0424.6621.820.803720.320.489562.047.684.42-2.557.78-1.992.55
Data as of Dec 01 2022. Currency figures normalised to GSK plc's reporting currency: UK Pound GBX

Institutional shareholders

20.41%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 01 Nov 2022145.60m3.58%
BlackRock Fund Advisorsas of 01 Nov 2022123.67m3.04%
Norges Bank Investment Managementas of 01 Nov 202293.46m2.30%
BlackRock Investment Management (UK) Ltd.as of 31 Oct 202282.62m2.03%
Dodge & Coxas of 30 Sep 202282.39m2.03%
Schroder Investment Management Ltd.as of 01 Nov 202270.13m1.72%
Silchester International Investors LLPas of 01 Nov 202266.61m1.64%
BlackRock Advisors (UK) Ltd.as of 01 Nov 202262.38m1.53%
Legal & General Investment Management Ltd.as of 01 Nov 202254.97m1.35%
SSgA Funds Management, Inc.as of 01 Nov 202248.48m1.19%
More ▼
Data from 31 Dec 2021 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.